Altamira Therapeutics to Hold 2022 Earnings and Business Updates Briefing on May 16, 2023


HAMILTON, Bermuda / ACCESSWIRE / May 12, 2023 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company focused on the development and commercialization of RNA delivery technology to extrahepatic targets, will hold 2022 financial results and business update briefing on Tuesday, May 16, 2023 announced. CEO Tomas Maier and COO Covadonga Paneda will deliver prepared remarks followed by a Q&A session to answer questions from investors and analysts.

event: Altamira Therapeutics 2022 Financial Results and Business Update Call
date: May 16 (Tue)

time: 8:00 AM ET (5:00 AM PT)


Investors will have access to the webcast 15 minutes before the call, where the operator will register your name and organization. The call will be in listen-only mode. To submit questions to the administrators, please email by the end of May

A replay of the call will be available 30 minutes after the live call from the investor section of the Altamira website (

Replay access:

Toll Free Replay Number: 877-481-4010
International call: 919-882-2331
Replay Passcode: 48448
Expires: May 30, 2023 at 11:59 PM ET

About Altamira Therapeutics

Altamira Therapeutics (NASDAQ:CYTO) is dedicated to developing RNA-based therapeutics (OligoPhore™ / SemaPhore™ delivery platform) against extrahepatic targets. The company now has two of his flagship siRNA programs in preclinical development beyond in vivo proof-of-concept: AM-401 for cancer with KRAS and AM-411 for rheumatoid arthritis. The versatile delivery platform is also suitable for mRNA and other types of RNA therapeutics and will be leveraged through out-licensing to pharmaceutical and biotech companies. In addition, Altamira has been approved for allergology and viral infections (Bentrio® OTC nasal spray, commercial) and inner ear treatment (AM-125 vertigo nasal spray, post-phase 2; Keyzilen® and Sonsuvi® for tinnitus and hearing loss; phase 3). Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with principal operations in Basel, Switzerland. For more information, please visit

investor contact

sauce: Altamira Therapeutics Inc.

View the source version on

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *